SOS1, ARHGEF1, and DOCK2 Rho-Gefs Mediate JAK-Dependent LFA-1 Activation by Chemokines

Total Page:16

File Type:pdf, Size:1020Kb

Load more

SOS1, ARHGEF1, and DOCK2 rho-GEFs Mediate JAK-Dependent LFA-1 Activation by Chemokines This information is current as Lara Toffali, Alessio Montresor, Michela Mirenda, Giorgio of September 24, 2021. Scita and Carlo Laudanna J Immunol 2017; 198:708-717; Prepublished online 16 December 2016; doi: 10.4049/jimmunol.1600933 http://www.jimmunol.org/content/198/2/708 Downloaded from Supplementary http://www.jimmunol.org/content/suppl/2016/12/15/jimmunol.160093 Material 3.DCSupplemental http://www.jimmunol.org/ References This article cites 36 articles, 19 of which you can access for free at: http://www.jimmunol.org/content/198/2/708.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision by guest on September 24, 2021 • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2017 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology SOS1, ARHGEF1, and DOCK2 rho-GEFs Mediate JAK-Dependent LFA-1 Activation by Chemokines Lara Toffali,*,† Alessio Montresor,*,† Michela Mirenda,* Giorgio Scita,‡,x and Carlo Laudanna*,† JAK-dependent activation of the rho module of integrin affinity triggering mediates chemokine-induced leukocyte adhesion. However, the signaling events linking JAKs to rho small GTPase activation by chemokines is still incompletely described. In this study, we show that son of sevenless 1 (SOS1), rho guanine nucleotide exchange factor (GEF)1 (ARHGEF1), and dedicator of cytokinesis (DOCK)2 GEFs mediate CXCL12-induced LFA-1 activation in human primary T lymphocytes. Downregulated expression of SOS1, ARHGEF1, and DOCK2 impairs LFA-1–mediated rapid T lymphocyte adhesion as well as underflow arrest on ICAM-1 induced by CXCL12. Moreover, LFA-1 affinity triggering by CXCL12 is impaired by SOS1, ARHGEF1, and DOCK2 downregulation. Notably, the three GEFs are all critically involved in chemokine-induced RhoA and Rac1 activation, thus Downloaded from suggesting the occurrence of a SOS1 specificity shift in the context of chemokine signaling. Accordingly, SOS1, ARHGEF1, and DOCK2 are tyrosine phosphorylated upon chemokine signaling with timing coherent with rapid LFA-1 affinity activation. Importantly, chemokine-induced tyrosine phosphorylation of these GEFs is fully mediated by JAK protein tyrosine kinases. Unexpectedly, and differently from VAV1, tyrosine phosphorylation of SOS1, ARHGEF1, and DOCK2 is completely inhibited by pertussis toxin pretreatment, thus suggesting different routes of rho-GEF triggering upon CXCR4 engagement. Taken together, these findings reveal a deeper level of complexity in the rho-signaling module, with at least four different rho-GEFs cooperating in http://www.jimmunol.org/ the regulation of chemokine-induced integrin activation, possibly suggesting the emergence of stochastic concurrency in signaling mechanisms controlling leukocyte trafficking. The Journal of Immunology, 2017, 198: 708–717. eukocyte recruitment is a central homeostatic process in cooperate to increase cell adhesiveness, integrin affinity upregu- the immune response. Although consisting of an ensemble lation plays a prominent role in rapid leukocyte arrest underflow L of continuous, mainly overlapping, cellular and bio- (2–5). Following G protein–coupled receptor engagement by chemical events, involving many different molecules both at the chemoattractants, a complex, still incompletely defined, inside-out qualitative and quantitative level, leukocyte recruitment is never- signaling network is assembled controlling the induction of by guest on September 24, 2021 theless modeled as a sequence of discrete steps, including cap- integrin conformational changes leading to increased affinity for turing, rolling, activation, arrest, crawling to sites of exit, and endothelial ligands. Among many investigated signaling events, transmigration through the barriers of endothelial cells and the Rho (3, 5) and Rap (6, 7) small GTPases are the most studied basement membrane. The transition from rolling to arrest, which is signaling mechanisms linking chemokine-triggered signal trans- the step when leukocytes become fully resistant to the pushing duction to rapid integrin affinity regulation. More recently, we force of the blood flow, is critically controlled by apically presented have demonstrated the critical role of protein tyrosine kinases chemoattractants, such as chemokines, leading to rapid integrin (PTKs) of JAKs, in particular JAK2 and JAK3, as upstream ac- activation (1). Although different modalities of integrin activation tivators of the rho module of LFA-1 affinity triggering in human T lymphocytes (8). In this context, we also started the character- ization of the biochemical link between JAKs and rho small *Department of Medicine, University of Verona, Verona 37134, Italy; †Center for Biomedical Computing, University of Verona, Verona 37134, Italy; GTPases demonstrating the involvement of VAV1 rho guanine ‡Italian Foundation for Cancer Research Institute for Molecular Oncology, Milan nucleotide exchange factor (GEF) in JAK-mediated rho module 20139, Italy; and xDepartment of Oncology and Hemato-Oncology, Italian Database of Operational Losses, University of Milan, Milan 20142, Italy activation by CXCL12. Small GTPase activity is tightly regulated by the rapid turnover Received for publication May 31, 2016. Accepted for publication November 16, 2016. between GDP/GTP-bound states, promoted by GTPase-specific This work was supported by Italian Association for Cancer Research Grant IG16797, GEFs. GEF activity is controlled by different mechanisms, in- Ministero dell’Istruzione, dell’Universita` e della Ricerca Grant PRIN 2009, Nano- cluding protein–protein interactions, protein–lipid interaction, medicine project funding from the University of Verona and the Fondazione Cariverona (to C.L.), Italian Association for Cancer Research Grant IG10168, European Research binding to second messengers, and posttranslational modifications Council Advanced Grant ERC 268836, and by Worldwide Cancer Research Grants (9). Tyrosine phosphorylation is one of the best characterized AICR-09-0582 and 14-0335 (to G.S.). mechanisms of GEF activation (10). For instance, phosphorylation Address correspondence and reprint requests to Prof. Carlo Laudanna, Department of of tyrosine 174 is crucial to VAV1 GEF activity (11). Moreover, Medicine, University of Verona, Strada le Grazie 8, Verona 37134, Italy. E-mail address: [email protected] son of sevenless 1 (SOS1), a ras-specific GEF, manifests a spec- The online version of this article contains supplemental material. ificity switch upon tyrosine phosphorylation, becoming capable of promoting GDP/GTP exchange on Rac1 (12, 13). Notably, VAV1 Abbreviations used in this article: ARHGEF1, rho guanine nucleotide exchange factor 1; DOCK, dedicator of cytokinesis; GEF, guanine nucleotide exchange factor; gene silencing causes only a partial inhibition of LFA-1 affinity P1, Penetratin 1; PTK, protein tyrosine kinase; PTx, pertussis toxin; siRNA, small triggering, and of RhoA and Rac1 activation, suggesting that other interfering RNA; SOS1, son of sevenless 1; TKIP, tyrosine kinase inhibitor peptide. rho-GEFs are at play in CXCL12-induced LFA-1 affinity upreg- Copyright Ó 2017 by The American Association of Immunologists, Inc. 0022-1767/17/$30.00 ulation. Consistent with the latter notion, dedicator of cytokinesis www.jimmunol.org/cgi/doi/10.4049/jimmunol.1600933 The Journal of Immunology 709 (DOCK)2 has been proposed to participate in VLA-4–mediated Human primary cells integrin activation (14). Moreover, JAK-mediated phosphorylation Human primary CD3+ lymphocytes were isolated from whole blood of of rho-GEF 1 (ARHGEF1) has been reported in an angiotensin II– healthy donors by Ficoll and Percoll gradients. Purity of T lymphocyte dependent murine vascular model of hypertension (15). preparation was evaluated by flow cytometry after staining with FITC- conjugated anti-CD3 Ab and was .95%. Isolated T lymphocytes were In this study, we pursued a deeper characterization of the upstream kept at 37˚C in standard adhesion buffer (PBS, 1 mM CaCl2, 1 mM MgCl2, signaling mechanisms linking JAK PTKs to integrin activation and 10% FBS [pH 7.2]) and used within 1 h. The University of Verona Ethics investigated the role of SOS1, ARHGEF1, and DOCK2 as media- Committee approved experimentation involving human primary cells. tors of chemokine-triggered JAK-dependent rho module activa- Static adhesion assay tion leading to LFA-1 affinity upregulation in human primary T lymphocytes. We show that SOS1, ARHGEF1, and DOCK2 are Human primary T lymphocytes were suspended at 3 3 106 cells/ml in phosphorylated on tyrosine by the CXCR4 ligand CXCL12 in a standard adhesion buffer. Adhesion assays were done on 18-well glass slides coated with human 1 mg/ml ICAM-1 in PBS; 20 ml of cell sus- time frame coherent with rapid integrin triggering. By using JAK-
Recommended publications
  • Deregulated Gene Expression Pathways in Myelodysplastic Syndrome Hematopoietic Stem Cells

    Deregulated Gene Expression Pathways in Myelodysplastic Syndrome Hematopoietic Stem Cells

    Leukemia (2010) 24, 756–764 & 2010 Macmillan Publishers Limited All rights reserved 0887-6924/10 $32.00 www.nature.com/leu ORIGINAL ARTICLE Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells A Pellagatti1, M Cazzola2, A Giagounidis3, J Perry1, L Malcovati2, MG Della Porta2,MJa¨dersten4, S Killick5, A Verma6, CJ Norbury7, E Hellstro¨m-Lindberg4, JS Wainscoat1 and J Boultwood1 1LRF Molecular Haematology Unit, NDCLS, John Radcliffe Hospital, Oxford, UK; 2Department of Hematology Oncology, University of Pavia Medical School, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; 3Medizinische Klinik II, St Johannes Hospital, Duisburg, Germany; 4Division of Hematology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden; 5Department of Haematology, Royal Bournemouth Hospital, Bournemouth, UK; 6Albert Einstein College of Medicine, Bronx, NY, USA and 7Sir William Dunn School of Pathology, University of Oxford, Oxford, UK To gain insight into the molecular pathogenesis of the the World Health Organization.6,7 Patients with refractory myelodysplastic syndromes (MDS), we performed global gene anemia (RA) with or without ringed sideroblasts, according to expression profiling and pathway analysis on the hemato- poietic stem cells (HSC) of 183 MDS patients as compared with the the French–American–British classification, were subdivided HSC of 17 healthy controls. The most significantly deregulated based on the presence or absence of multilineage dysplasia. In pathways in MDS include interferon signaling, thrombopoietin addition, patients with RA with excess blasts (RAEB) were signaling and the Wnt pathways. Among the most signifi- subdivided into two categories, RAEB1 and RAEB2, based on the cantly deregulated gene pathways in early MDS are immuno- percentage of bone marrow blasts.
  • Anti-ARL4A Antibody (ARG41291)

    Anti-ARL4A Antibody (ARG41291)

    Product datasheet [email protected] ARG41291 Package: 100 μl anti-ARL4A antibody Store at: -20°C Summary Product Description Rabbit Polyclonal antibody recognizes ARL4A Tested Reactivity Hu, Ms, Rat Tested Application ICC/IF, IHC-P Host Rabbit Clonality Polyclonal Isotype IgG Target Name ARL4A Antigen Species Human Immunogen Recombinant fusion protein corresponding to aa. 121-200 of Human ARL4A (NP_001032241.1). Conjugation Un-conjugated Alternate Names ARL4; ADP-ribosylation factor-like protein 4A Application Instructions Application table Application Dilution ICC/IF 1:50 - 1:200 IHC-P 1:50 - 1:200 Application Note * The dilutions indicate recommended starting dilutions and the optimal dilutions or concentrations should be determined by the scientist. Calculated Mw 23 kDa Properties Form Liquid Purification Affinity purified. Buffer PBS (pH 7.3), 0.02% Sodium azide and 50% Glycerol. Preservative 0.02% Sodium azide Stabilizer 50% Glycerol Storage instruction For continuous use, store undiluted antibody at 2-8°C for up to a week. For long-term storage, aliquot and store at -20°C. Storage in frost free freezers is not recommended. Avoid repeated freeze/thaw cycles. Suggest spin the vial prior to opening. The antibody solution should be gently mixed before use. Note For laboratory research only, not for drug, diagnostic or other use. www.arigobio.com 1/2 Bioinformation Gene Symbol ARL4A Gene Full Name ADP-ribosylation factor-like 4A Background ADP-ribosylation factor-like 4A is a member of the ADP-ribosylation factor family of GTP-binding proteins. ARL4A is similar to ARL4C and ARL4D and each has a nuclear localization signal and an unusually high guaninine nucleotide exchange rate.
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus

    A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus

    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
  • The Multifaceted Role of CMA in Glioma: Enemy Or Ally?

    The Multifaceted Role of CMA in Glioma: Enemy Or Ally?

    International Journal of Molecular Sciences Review The Multifaceted Role of CMA in Glioma: Enemy or Ally? Alessia Lo Dico 1,† , Cristina Martelli 1,† , Cecilia Diceglie 1 and Luisa Ottobrini 1,2,* 1 Department of Pathophysiology and Transplantation, University of Milan, Via F.Cervi 93, Segrate, 20090 Milan, Italy; [email protected] (A.L.D.); [email protected] (C.M.); [email protected] (C.D.) 2 Institute of Molecular Bioimaging and Physiology, National Research Council (IBFM-CNR), Via F.Cervi 93, Segrate, 20090 Milan, Italy * Correspondence: [email protected]; Tel.: +39-02(50)-330-404; Fax: +39-02(50)-330-425 † Authors contributed equally to this work. Abstract: Chaperone-mediated autophagy (CMA) is a catabolic pathway fundamental for cell home- ostasis, by which specific damaged or non-essential proteins are degraded. CMA activity has three main levels of regulation. The first regulatory level is based on the targetability of specific proteins possessing a KFERQ-like domain, which can be recognized by specific chaperones and delivered to the lysosomes. Target protein unfolding and translocation into the lysosomal lumen constitutes the second level of CMA regulation and is based on the modulation of Lamp2A multimerization. Finally, the activity of some accessory proteins represents the third regulatory level of CMA activity. CMA’s role in oncology has not been fully clarified covering both pro-survival and pro-death roles in different contexts. Taking all this into account, it is possible to comprehend the actual complexity of both CMA regulation and the cellular consequences of its activity allowing it to be elected as a modulatory and not only catabolic machinery.
  • Targeting PH Domain Proteins for Cancer Therapy

    Targeting PH Domain Proteins for Cancer Therapy

    The Texas Medical Center Library DigitalCommons@TMC The University of Texas MD Anderson Cancer Center UTHealth Graduate School of The University of Texas MD Anderson Cancer Biomedical Sciences Dissertations and Theses Center UTHealth Graduate School of (Open Access) Biomedical Sciences 12-2018 Targeting PH domain proteins for cancer therapy Zhi Tan Follow this and additional works at: https://digitalcommons.library.tmc.edu/utgsbs_dissertations Part of the Bioinformatics Commons, Medicinal Chemistry and Pharmaceutics Commons, Neoplasms Commons, and the Pharmacology Commons Recommended Citation Tan, Zhi, "Targeting PH domain proteins for cancer therapy" (2018). The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Dissertations and Theses (Open Access). 910. https://digitalcommons.library.tmc.edu/utgsbs_dissertations/910 This Dissertation (PhD) is brought to you for free and open access by the The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences at DigitalCommons@TMC. It has been accepted for inclusion in The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Dissertations and Theses (Open Access) by an authorized administrator of DigitalCommons@TMC. For more information, please contact [email protected]. TARGETING PH DOMAIN PROTEINS FOR CANCER THERAPY by Zhi Tan Approval page APPROVED: _____________________________________________ Advisory Professor, Shuxing Zhang, Ph.D. _____________________________________________
  • Mutation of Vav1 Adaptor Region Reveals a New Oncogenic Activation

    Mutation of Vav1 Adaptor Region Reveals a New Oncogenic Activation

    www.impactjournals.com/oncotarget/ Oncotarget, Vol. 6, No.4 Mutation of Vav1 adaptor region reveals a new oncogenic activation Lyra Razanadrakoto1,2,*, Françoise Cormier3,4,5,*, Vanessa Laurienté1,2, Elisabetta Dondi1,2, Laura Gardano1,2, Shulamit Katzav6, Lionel Guittat1,2 and Nadine Varin- Blank1,2 1 INSERM, UMR 978, Bobigny, France 2 PRES SPC, Labex Inflamex, Université Paris 13, UFR SMBH, Bobigny, France 3 INSERM, UMR 1016, Institut Cochin, Paris, France 4 CNRS, UMR 8104, Paris, France 5 PRES SPC, Université Paris Descartes, Paris, France 6 The Hebrew University/ Hadassah Medical School, Jerusalem, Israel * These authors share co-first authorship Correspondence to: Nadine Varin-Blank, email: [email protected] Correspondence to: Lionel Guittat, email: [email protected] Keywords: Vav1, β-catenin, Rac GTPase, Src-homology domains, adhesion complex, tumorigenesis Received: May 14, 2014 Accepted: October 23, 2014 Published: October 24 2014 This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT Vav family members function as remarkable scaffold proteins that exhibit both GDP/GTP exchange activity for Rho/Rac GTPases and numerous protein-protein interactions via three adaptor Src-homology domains. The exchange activity is under the unique regulation by phosphorylation of tyrosine residues hidden by intra-molecular interactions. Deletion of the autoinhibitory N-terminal region results in an oncogenic protein, onco-Vav, leading to a potent activation of Rac GTPases whereas the proto-oncogene barely leads to transformation. Substitution of conserved residues of the SH2-SH3 adaptor region in onco-Vav reverses oncogenicity.
  • SUPPLEMENTARY APPENDIX Inflammation Regulates Long Non-Coding RNA-PTTG1-1:1 in Myeloid Leukemia

    SUPPLEMENTARY APPENDIX Inflammation Regulates Long Non-Coding RNA-PTTG1-1:1 in Myeloid Leukemia

    SUPPLEMENTARY APPENDIX Inflammation regulates long non-coding RNA-PTTG1-1:1 in myeloid leukemia Sébastien Chateauvieux, 1,2 Anthoula Gaigneaux, 1° Déborah Gérard, 1 Marion Orsini, 1 Franck Morceau, 1 Barbora Orlikova-Boyer, 1,2 Thomas Farge, 3,4 Christian Récher, 3,4,5 Jean-Emmanuel Sarry, 3,4 Mario Dicato 1 and Marc Diederich 2 °Current address: University of Luxembourg, Faculty of Science, Technology and Communication, Life Science Research Unit, Belvaux, Luxemburg. 1Laboratoire de Biologie Moléculaire et Cellulaire du Cancer, Hôpital Kirchberg, Luxembourg, Luxembourg; 2College of Pharmacy, Seoul National University, Gwanak-gu, Seoul, Korea; 3Cancer Research Center of Toulouse, UMR 1037 INSERM/ Université Toulouse III-Paul Sabatier, Toulouse, France; 4Université Toulouse III Paul Sabatier, Toulouse, France and 5Service d’Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopôle, Toulouse, France Correspondence: MARC DIEDERICH - [email protected] doi:10.3324/haematol.2019.217281 Supplementary data Inflammation regulates long non-coding RNA-PTTG1-1:1 in myeloid leukemia Sébastien Chateauvieux1,2, Anthoula Gaigneaux1*, Déborah Gérard1, Marion Orsini1, Franck Morceau1, Barbora Orlikova-Boyer1,2, Thomas Farge3,4, Christian Récher3,4,5, Jean-Emmanuel Sarry3,4, Mario Dicato1 and Marc Diederich2 1 Laboratoire de Biologie Moléculaire et Cellulaire du Cancer, Hôpital Kirchberg, 9, rue Edward Steichen, 2540 Luxembourg, Luxemburg; 2 College of Pharmacy, Seoul National University, 1 Gwanak-ro,
  • Gene Ontology Functional Annotations and Pleiotropy

    Gene Ontology Functional Annotations and Pleiotropy

    Network based analysis of genetic disease associations Sarah Gilman Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy under the Executive Committee of the Graduate School of Arts and Sciences COLUMBIA UNIVERSITY 2014 © 2013 Sarah Gilman All Rights Reserved ABSTRACT Network based analysis of genetic disease associations Sarah Gilman Despite extensive efforts and many promising early findings, genome-wide association studies have explained only a small fraction of the genetic factors contributing to common human diseases. There are many theories about where this “missing heritability” might lie, but increasingly the prevailing view is that common variants, the target of GWAS, are not solely responsible for susceptibility to common diseases and a substantial portion of human disease risk will be found among rare variants. Relatively new, such variants have not been subject to purifying selection, and therefore may be particularly pertinent for neuropsychiatric disorders and other diseases with greatly reduced fecundity. Recently, several researchers have made great progress towards uncovering the genetics behind autism and schizophrenia. By sequencing families, they have found hundreds of de novo variants occurring only in affected individuals, both large structural copy number variants and single nucleotide variants. Despite studying large cohorts there has been little recurrence among the genes implicated suggesting that many hundreds of genes may underlie these complex phenotypes. The question
  • Vav1 (D45G3) Rabbit Mab A

    Vav1 (D45G3) Rabbit Mab A

    Revision 1 C 0 2 - t Vav1 (D45G3) Rabbit mAb a e r o t S Orders: 877-616-CELL (2355) [email protected] Support: 877-678-TECH (8324) 7 5 Web: [email protected] 6 www.cellsignal.com 4 # 3 Trask Lane Danvers Massachusetts 01923 USA For Research Use Only. Not For Use In Diagnostic Procedures. Applications: Reactivity: Sensitivity: MW (kDa): Source/Isotype: UniProt ID: Entrez-Gene Id: WB, IP H Endogenous 95 Rabbit IgG P15498 7409 Product Usage Information Application Dilution Western Blotting 1:1000 Immunoprecipitation 1:50 Storage Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody. Specificity / Sensitivity Vav1 (D45G3) Rabbit mAb recognizes endogenous levels of total Vav1 protein. Species Reactivity: Human Species predicted to react based on 100% sequence homology: Monkey Source / Purification Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues in the carboxy terminus of human Vav1 protein. Background Vav proteins belong to the Dbl family of guanine nucleotide exchange factors (GEFs) for Rho/Rac small GTPases. The three identified mammalian Vav proteins (Vav1, Vav2 and Vav3) differ in their expression. Vav1 is expressed only in hematopoietic cells and is involved in the formation of the immune synapse. Vav2 and Vav3 are more ubiquitously expressed. Vav proteins contain the Dbl homology domain, which confers GEF activity, as well as protein interaction domains that allow them to function in pathways regulating actin cytoskeleton organization (reviewed in 1).
  • MERTK-Mediated Signaling in the Retinal Pigment Epithelium: Insights Into the Mechanism of RPE Phagocytosis

    MERTK-Mediated Signaling in the Retinal Pigment Epithelium: Insights Into the Mechanism of RPE Phagocytosis

    MERTK-mediated Signaling in the Retinal Pigment Epithelium: Insights into the Mechanism of RPE Phagocytosis by Shameka J. Shelby A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy (Biological Chemistry) in The University of Michigan 2012 Doctoral Committee: Professor Debra A. Thompson, Chair Professor Christin Carter-Su Professor Bret A. Hughes Professor Benjamin L. Margolis Assistant Professor Hisashi Umemori © Shameka J. Shelby 2012 To my two favorite men, Juan and Zani for your patience, love, and support. ii Acknowledgements I would like to acknowledge all of the people who helped me to accomplish my goals. My mentor, Dr. Debra Thompson, has been instrumental in my success as a scientist. Her motherly guidance has helped to mold me into the person and scientist I am today. I’m overly grateful for her tireless efforts and patience during the course of my graduate career. I wouldn’t have even considered graduate school without the guidance of my undergraduate advisors, Drs. Marion Carroll and Guangdi Wang, to whom I am also grateful. Also, my favorite high school teacher Mrs. Jenkins incited my passion for biology and encouraged me to follow my aspirations. I am also grateful for the invaluable input and criticisms of my committee members, Drs. Bret Hughes, Christin Carter-Su, Hisashi Umemori, and Benjamin Margolis. I would especially like to thank Dr. Hughes, Dr. Carter-Su, and Dr. Margolis for reagents that were instrumental in the completion of my experiments. Ben literally saved my life with the plethora of antibodies he provided. Reagents and clones provided by Drs.
  • Identification of Fusion Genes in Breast Cancer by Paired-End RNA

    Identification of Fusion Genes in Breast Cancer by Paired-End RNA

    Edgren et al. Genome Biology 2011, 12:R6 http://genomebiology.com/2011/12/1/R6 RESEARCH Open Access Identification of fusion genes in breast cancer by paired-end RNA-sequencing Henrik Edgren1†, Astrid Murumagi1†, Sara Kangaspeska1†, Daniel Nicorici1, Vesa Hongisto2, Kristine Kleivi2,3, Inga H Rye3, Sandra Nyberg2, Maija Wolf1, Anne-Lise Borresen-Dale1,4, Olli Kallioniemi1* Abstract Background: Until recently, chromosomal translocations and fusion genes have been an underappreciated class of mutations in solid tumors. Next-generation sequencing technologies provide an opportunity for systematic characterization of cancer cell transcriptomes, including the discovery of expressed fusion genes resulting from underlying genomic rearrangements. Results: We applied paired-end RNA-seq to identify 24 novel and 3 previously known fusion genes in breast cancer cells. Supported by an improved bioinformatic approach, we had a 95% success rate of validating gene fusions initially detected by RNA-seq. Fusion partner genes were found to contribute promoters (5’ UTR), coding sequences and 3’ UTRs. Most fusion genes were associated with copy number transitions and were particularly common in high-level DNA amplifications. This suggests that fusion events may contribute to the selective advantage provided by DNA amplifications and deletions. Some of the fusion partner genes, such as GSDMB in the TATDN1-GSDMB fusion and IKZF3 in the VAPB-IKZF3 fusion, were only detected as a fusion transcript, indicating activation of a dormant gene by the fusion event. A number of fusion gene partners have either been previously observed in oncogenic gene fusions, mostly in leukemias, or otherwise reported to be oncogenic. RNA interference-mediated knock-down of the VAPB-IKZF3 fusion gene indicated that it may be necessary for cancer cell growth and survival.
  • VAV Proteins As Double Agents in Cancer: Oncogenes with Tumor Suppressor Roles

    VAV Proteins As Double Agents in Cancer: Oncogenes with Tumor Suppressor Roles

    biology Review VAV Proteins as Double Agents in Cancer: Oncogenes with Tumor Suppressor Roles Myriam Cuadrado 1,2 and Javier Robles-Valero 1,2,* 1 Centro de Investigación del Cáncer, CSIC-University of Salamanca, 37007 Salamanca, Spain; [email protected] 2 Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), CSIC-University of Salamanca, 37007 Salamanca, Spain * Correspondence: [email protected] Simple Summary: The role of the VAV family (comprised of VAV1, VAV2, and VAV3) in proactive pathways involved in cell transformation has been historically assumed. Indeed, the discovery of potential gain-of-function VAV1 mutations in specific tumor subtypes reinforced this functional archetype. Contrary to this paradigm, we demonstrated that VAV1 could unexpectedly act as a tumor suppressor in some in vivo contexts. In this review, we discuss recent findings in the field, where the emerging landscape is one in which GTPases and their regulators, such as VAV proteins, can exhibit tumor suppressor functions. Abstract: Guanosine nucleotide exchange factors (GEFs) are responsible for catalyzing the transition of small GTPases from the inactive (GDP-bound) to the active (GTP-bound) states. RHO GEFs, including VAV proteins, play essential signaling roles in a wide variety of fundamental cellular processes and in human diseases. Although the most widespread archetype in the field is that RHO Citation: Cuadrado, M.; Robles-Valero, GEFs exert proactive functions in cancer, recent studies in mice and humans are providing new J. VAV Proteins as Double Agents in insights into the in vivo function of these proteins in cancer. These results suggest a more complex Cancer: Oncogenes with Tumor scenario where the role of GEFs is not so clearly defined.